Clinical Significance of G Protein-Coupled Receptor 110 (GPR110) as a Novel Prognostic Biomarker in Osteosarcoma
Zhiqiang Liu, Guorong Zhang, Changlei Zhao, Juming Li
Department of Rehabilitation, Yidu Central Hospital of Weifang, Weifang, Shandong, China (mainland)
Med Sci Monit 2018; 24: CLR5216-5224
Available online: 2018-07-27
G protein-coupled receptor 110 (GPR110) belongs to the subfamily of the adhesion G protein-coupled receptors (GPCRs). The potential role of GPR110 has been correlated with cancer cell invasion in some tumors such as glioma. However, its expression and role in human osteosarcoma has not been identified. This study aimed to examine the expression level of GPR110 and determine whether the expression of GPR110 was correlated with aggressive clinicopathological characteristics and prognosis of osteosarcoma.
MATERIAL AND METHODS: This retrospective study included 94 osteosarcoma patients. Immunohistochemistry staining and quantitative real-time polymerase chain reaction were performed to detect the expression level of GPR110 in osteosarcoma specimens. We then determined the correlation of the GPR110 expression with the clinicopathological characteristics and prognosis by univariate or multivariate analysis. Patient outcomes were evaluated using the Kaplan-Meier log-rank test and prognostic factors were detected by multivariate analysis. The function of GPR110 on cell proliferation, migration, and invasion were examined in this in vitro study.
RESULTS: Overexpression of GPR110 was correlated with the advanced stage of osteosarcoma. Patients with high expression level of GPR110 had significantly poorer 5-year overall survival; the multivariate analysis found that GPR110 expression level can act as an independent prognosis factor. Knockdown of GPR110 can decrease the proliferation, migration, and invasion capacity of human osteosarcoma cell lines.
CONCLUSIONS: Our studies suggest a role of GPR110 in tumor progression and as a potential novel prognostic biomarker in osteosarcoma.